Valence Discovery Inc.

Based in Canada, Valence Discovery Inc. is a biotechnology firm dedicated to transforming drug discovery through advanced AI-driven computational modeling, enhancing the efficiency and accuracy of the drug development process. Founded in 2018 and headquartered in Montreal, Canada, Valence Discovery Inc. specializes in the development of AI technologies for drug discovery.

The company has executed 2 total deals, with its most recent transaction occurring on May 8, 2023. In this deal, Valence Discovery was acquired by Recursion Pharmaceuticals, Inc. for USD 47. 50 million.

The founders, Prudencio Tossou and Therence Bois, have previous experience in biotechnology ventures, contributing to Valence's innovative approach. The company issued a total of USD 10. 90 mn in funding across its investment rounds, with Recursion Pharmaceuticals being the lead investor in the latest round, which was an Add-on round. Valence Labs, a crucial segment of Valence Discovery, is renowned for its AI research focusing on drug discovery.

The flagship product, TxPert, employs advanced biological knowledge networks to predict cellular responses to genetic modifications. This technology enhances drug discovery accuracy by simulating virtual cellular responses to various interventions. Valence Labs serves pharmaceutical companies and research institutions globally, targeting key markets in North America, Europe, and parts of Asia, where there is a significant demand for advanced biotechnological solutions. Valence Labs' revenue is generated through strategic partnerships with pharmaceutical companies, research institutions, and biotech firms.

The company structures its agreements around service contracts, providing clients access to advanced data analytics and computational capabilities. By leveraging Recursion's extensive 60 petabyte data repository, Valence Labs crafts tailored solutions for drug development. Their business model includes subscription services for ongoing access to predictive tools and project-based fees for specific applications of their technology, with TxPert being a vital component in these agreements. Following its acquisition by Recursion Pharmaceuticals, Inc.

, Valence Discovery plans to enhance its AI biotechnology capabilities. The funding from the recent deal, valued at USD 47. 50 million, aims to support the development of new products and technology enhancements. The company intends to expand its reach into additional international markets, focusing on enhancing its presence in Europe and Asia by the end of 2024.

This expansion will align with their goals of increasing access to their innovative drug discovery solutions.